15th July 2022 | Pharma Updates
Pharma seems to be prime area to hide during recession
Due to the influx of investors into an industry recognized for surviving recessions quite well, drug stocks may continue to outperform the broader market. Investors may be excused for paying closer attention to the Federal Reserve as pharma companies report profits next week.
Medinnbelle Hervalcare to sell Endura Mass to Cipla Health
Pharma major Cipla Ltd said that its subsidiary Cipla Health Ltd has inked contracts with specific terms to buy Medinnbelle Herbalcare’s Endura Mass nutritional supplement brand for an undisclosed amount.
ICMR issued Standard Treatment Guidelines for 54 ailments
World Health Organization, the National Health Authority, and the Indian Council of Medical Research (ICMR) have released the third volume of Standard Treatment Workflows (STWs), which covers 54 diseases.
6-7% growth in Indian pharma companies predicted by ICRA for FY2023
After experiencing Y-o-Y revenue growth of 8.5% in Q4 FY2022 and 7.7% in FY2022 to reach Rs 1.87 lakh crore, the revenue growth of ICRA’s sample set of 16 Indian pharmaceutical businesses is predicted to reduce to 6-7% in FY2023.
Bayer to sell the testosterone medicine for up to 500 million euros
German chemical company Bayer said that it would sell the male testosterone replacement therapy Nebido for up to €500 million in order to focus on medical innovation.
Sanofi's Zantac marketing claims criticized by J&J
Sanofi was directed by the National Advertising Division to remove some of its Zantac marketing claims at the same time that the business is being sued over allegedly deceptive Icy Hot pain patch promotion.
Anumana and Novartis collaborate to use AI to identify cardiac problems
Health technology company Anumana and Novartis Pharmaceuticals Corporation have struck a cooperation to deploy artificial intelligence (AI) for the identification of cardiac disorders.